<DOC>
	<DOCNO>NCT01291420</DOCNO>
	<brief_summary>The aim study evaluate immunogenicity clinical efficacy intradermal vaccination autologous RNA-modified dendritic cell ( DCs ) - engineer express WT1 protein - patient limited spread metastatic solid tumor , i.e . breast cancer , glioblastoma grade IV , sarcoma , malignant mesothelioma colorectal tumor . Based result previously perform phase I study autologous WT1 mRNA-transfected DC , investigator hypothesize vaccination DC well-tolerated result increase WT1-specific CD8+ T cell response .</brief_summary>
	<brief_title>Dendritic Cell Vaccination Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Mesothelioma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . Tumor type : Metastatic Locally Advanced Breast Cancer ; Malignant Mesothelioma ; Glioblastoma Multiforme ( Grade IV ) ; Sarcoma 's ; Colorectal tumor rare tumor ( less 500 patient year ) 2 . Extent disease : Metastatic Breast Cancer High Risk Locally Advanced Breast Cancer Partial Complete response first line chemotherapy metastatic locally advanced breast cancer . Minimal metastatic disease hormonal treatment High risk Locally Advanced breast cancer define ( and/or ) : Age &lt; 60 year old ER , PR Her2 Neu negative tumor &gt; 4 lymphnodes initial presentation Mastitis Carcinomatosis Pregnancy associate Breast Cancer Malignant Mesothelioma : Partial Complete response first line chemotherapy amendable surgery Adjuvant debulking surgery Glioblastoma Multiforme In Recurrent Disease optimal treatment accord Stupp regimen In primary disease debulking surgery , Temodal/radiotherapy Temodal chemotherapy 6 month Sarcoma 's After adjuvant chemotherapy uterine sarcoma 's After Optimal Debulking Surgery liposarcoma 's , synovial cell sarcoma 's Recurrent sarcoma 's limited disease Colorectal tumor Kras wildtype tumor inoperable lymphnode metastasis standard chemotherapy ( FOLFOX , FOLFIRI ) 3 . Patient Characteristics Prior treatment : Patients must receive least one prior chemotherapeutic regimen must 1 month past last treatment . Age : ≥ 18 year old Performance status : WHO PS grade 01 ( Appendix B ) Objectively assessable parameter life expectancy : 3 month Prior concomitant associate disease allow exception underlie autoimmune disease positive serology HIV/HBV/HCV No concomitant use immunosuppressive drug , hormonal treatment breast cancer allow case stable disease Adequate renal liver function , i.e . creatinin bilirubin = 1.2 time upper limit normal Absence psychological , familial , sociological geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial Women childbearing potential use adequate contraception prior study entry duration study participation 1 . Subjects concurrent additional malignancy ( exception nonmelanoma skin cancer carcinoma situ cervix ) 2 . Subjects pregnant 3 . Subjects sensitivity drug provide local anesthesia 4 . Subjects need corticosteroid 1 mg/kg vaccination ; corticosteroid allow part treatment take ≥ 30 day start vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>